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Abstract
Background Because of the distinct clinical presentation of
early and advanced stage ovarian cancer, we aim to clarify
whether these disease entities are solely separated by time of
diagnosis or whether they arise from distinct molecular
events.
Methods Sixteen early and sixteen advanced stage ovar-
ian carcinomas, matched for histological subtype and
differentiation grade, were included. Genomic aberra-
tions were compared for each early and advanced stage
ovarian cancer by array comparative genomic hybridiza-
tion. To study how the aberrations correlate to the
Afra Zaal and Wouter J. Peyrot contributed equally to this paper.
Electronic supplementary material The online version of this article
(doi:10.1007/s13402-012-0077-5) contains supplementary material,
which is available to authorized users.
A. Zaal (*) :W. J. Peyrot : J. H. W. Veerbeek :
R. H. M. Verheijen : R. P. Zweemer
Department of Gynaecological Oncology,
University Medical Center Utrecht,
PO Box 85500, 3508 GA Utrecht, The Netherlands
e-mail: a.zaal@umcutrecht.nl
P. M. J. J. Berns :M. E. L. van der Burg
EORTC Gynaecological Cancer Group
Translational Research Group chair,
Avenue Mounierlaan 83/11,
1200 Brussels, Belgium
P. M. J. J. Berns :M. E. L. van der Burg
Department of Medical Oncology, Erasmus MC;
University Medical Center Rotterdam,
PO Box 2040, 3000 CA Rotterdam, The Netherlands
J. B. Trimbos
Study Coordinator EORTC-ACTION trial, Department of
Gynaecological Oncology, Leiden University Medical Center,
PO Box 9600, 2300 RC Leiden, The Netherlands
I. Cadron : I. Vergote
Department of Gynecologic Oncology,
University Hospitals Leuven,
Herestraat 49,
3000 Leuven, Belgium
P. J. van Diest
Department of Pathology, University Medical Center Utrecht,
PO Box 85500, 3508 GA Utrecht, The Netherlands
W. N. van Wieringen
Department of Biostatistics and Epidemiology,
VU University Medical Center,
PO Box 7057, 1007 MB Amsterdam, The Netherlands
W. N. van Wieringen
Department of Mathematics, VU University Medical Center,
PO Box 7057, 1007 MB Amsterdam, The Netherlands
O. Krijgsman :G. A. Meijer :B. Ylstra
Department of Pathology, VU University Medical Center,
PO Box 7057, 1007 MB Amsterdam, The Netherlands
Cell Oncol. (2012) 35:181–188
DOI 10.1007/s13402-012-0077-5
clinical characteristics of the tumors we clustered tumors
based on the genomic aberrations.
Results The genomic aberration patterns in advanced stage
cancer equalled those in early stage, but were more frequent
in advanced stage (p00.012). Unsupervised clustering
based on genomic aberrations yielded two clusters that
significantly discriminated early from advanced stage (p0
0.001), and that did differ significantly in survival (p0
0.002). These clusters however did give a more accurate
prognosis than histological subtype or differentiation grade.
Conclusion This study indicates that advanced stage ovar-
ian cancer either progresses from early stage or from a
common precursor lesion but that they do not arise from
distinct carcinogenic molecular events. Furthermore, we
show that array comparative genomic hybridization has the
potential to identify clinically distinct patients.
Keywords Oligonucleotide array . Ovarian neoplasms .
Chromosome aberrations . Neoplasm staging . Prognosis
1 Introduction
Despite improved survival over the last decades, ovarian cancer
is still the most lethal gynaecological malignancy in theWestern
world, with a 5-year overall survival of only 25 % for advanced
stage [1, 2]. In contrast, patients diagnosed at an early stage have
a good 5-year overall survival rate of 93 %. Early stage ovarian
cancer, however, is only diagnosed in 19 % of the patients.
Like other malignancies, epithelial ovarian cancer presum-
ably results from an accumulation of genomic aberrations [3],
but the exact molecular pathways by which these tumors
develop have not been fully elucidated [4, 5]. For other
tumors, such as cervical and anal cancer, intraepithelial neo-
plasia is known to be a precursor lesion. However, no clear
precursor lesion is known for ovarian cancer. Therefore, the
first clinical entity to study carcinogenesis of ovarian cancer in
patients is minimal localized cancer (FIGO stage I disease).
As a small percentage of the patients is diagnosed with early
stage ovarian cancer, it has been hypothesized that early and
advanced stage ovarian cancers are two distinct subtypes.
Early stage ovarian cancer (with a good prognosis) may
represent a distinct biological entity with low metastatic po-
tential and would thus arise through a different carcinogenic
pathway. It has been suggested that these early cases are
molecularly distinguishable from the advanced stage ovarian
cancer with a worse prognosis [6].
Copy number change is one of the key features of genetic
instability in human cancer and can be measured in formalin-
fixed, paraffin embedded tissue (FFPE)[7]. To test the hypoth-
esis that early and advanced stage ovarian cancers are distinct
molecular pathologic entities, we used array comparative ge-
nomic hybridization (array CGH) to detect and compare ge-
nomic aberrations in matched early and advanced stage
ovarian tumors. Furthermore, we study how the aberrations
correlate to the clinical characteristics of the tumors[8].
2 Materials and methods
2.1 Patients and tumor tissue
FFPE primary ovarian tumor tissue of 52 early stage ovarian
cancer patients (FIGO stage I), was available from 448 partic-
ipants of the EORTC ‘Adjuvant ChemoTherapy in Ovarian
Neoplasm’ (ACTION) trial [9–11]. Of these 52 samples, 17
early stage samples with high quality DNAwere matched for
histological subtype and grade with FIGO stage III–IV (ad-
vanced stage) ovarian cancer samples from the Departments of
Pathology of the University Medical Center Utrecht and VU
University Medical Center Amsterdam, The Netherlands.
FIGO stage was determined by optimal staging in all but four
of the patients with advanced stage cancer. Staging was opti-
mal (n07), modified (n03) or minimal (n07) as previously
described [9]. In short, optimal staging consisted of inspection
and palpation of all peritoneal surfaces; biopsies of any suspect
lesions for metastases; peritoneal washing; infracolic omentec-
tomy; (blind) biopsies of right hemidiaphragm, of right and left
paracolic gutter, of pelvic sidewalls, of ovarian fossa, of blad-
der peritoneum, and of cul-de-sac; sampling of iliac and peri-
aortic lymph nodes. Modified comprised of everything
between optimal and minimal staging. Minimal staging was
only inspection and palpation of all peritoneal surfaces and the
retroperitoneal area; biopsies of any suspect lesions for metas-
tases; peritoneal washing and infracolic omentectomy.
All samples were revised by an experienced gynaecolog-
ical/oncological pathologist (PvD). The tumor percentage
was defined by the pathologist per individual case; mean
77.8 % (SD 7.5), median 80 % range [65–95]. Samples were
processed anonymously in accordance with institutional
ethical guidelines, and follow up was retrieved through the
EORTC ACTION trial database and the hospital informa-
tion system for the early and advanced stage tumors respec-
tively. Overall and progression free survival times were
calculated from the time of randomization (within 6 weeks
following staging) or the date of surgery for the early and
advanced stage tumors respectively.
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The age range was 27–80 years with a mean of 52 years
for early and 62 years for advanced stage carcinomas. In six
cases, an exact match for grade was unavailable. In these
cases we matched with one grade difference being a grade 1
early with grade 2 advanced (n04), and a grade 2 early with
grade 3 advanced (n02) (Table 1).
2.2 DNA isolation and detection of genomic aberrations
by array CGH
Tumor tissue was dissected from freshly cut 10 μm FFPE
sections after confirming the tumor area by parallel haematox-
ylin and eosin staining. DNA was isolated as previously
described [7, 12] using the QIAamp DNA micro kit (Qiagen,
Hilden, Germany). DNA concentration and labelling quality
were measured using NanoDrop 1000 Spectrophotometer
(Thermo Scientific, Wilmington, DE, USA). Labelling with
cyanine 3-dUTP (Cy3) and cyanine 5-dUTP (Cy5) nucleotides
was performed using the array CGH labelling kit for oligo
arrays according to the manufacturer’s protocol (Enzo Life
Sciences, Farmingdale, NY, USA). DNA isolated from blood
obtained from eighteen healthy females was pooled for use as a
normal reference [13]. Free nucleotides were removed using
the MinElute PCR Purification Kit (Qiagen). DNA was hy-
bridized to 105 K whole genome Oxford design microarrays
containing over 99.000 unique in situ synthesized 60-mer
Table 1 Characteristics of all 32 patients included in this study.
Overall (OS) and progression free survival (PFS) are calculated from
time of randomization in the early (T102-T118) and time of diagnosis
in advanced stage group (T302-T318). Histological subtypes are
indicated as clearcell (C), endometrioid (E), mucinous (M) or serous
(S). Adjuvant Chemotherapy (CT) was administered to a subset of
patients. The results of the unsupervised clustering analysis are dis-
played as cluster A or B
Sample Age Stage Type Grade CT Staging Status OS (month) Progression PFS (months) Cluster
T102 70 Ic capsule ruptured C 2 no optimal Alive 42 no 42 A
T103 61 Ic capsule ruptured C 3 yes optimal Alive 154 no 154 A
T104 61 Ia C 3 yes optimal Dead 13 yes 10 A
T105 47 Ia C 3 no minimal Alive 136 no 136 A
T106 64 Ic capsule ruptured C 3 no optimal Alive 39 no 39 A
T108 41 Ic capsule ruptured E 1 yes minimal Alive 73 no 73 A
T109 55 Ib E 1 yes minimal Alive 137 no 137 A
T110 64 Ic ascites positive E 1 no modified Alive 49 yes 49 A
T111 46 Ic ovarian surface E 2 no minimal Alive 146 no 146 A
T112 53 Ic capsule ruptured E 2 yes minimal Alive 44 no 44 A
T113 42 Ic capsule ruptured M 1 no optimal Alive 69 no 69 A
T114 35 Ia M 2 no optimal Alive 152 no 152 A
T115 27 Ia S 1 yes minimal Alive 65 no 65 A
T116 62 Ia S 1 no minimal Alive 59 no 59 B
T117 50 Ic ascites positive S 1 no modified Dead 61 yes 7 B
T118 53 Ia ovarian surface S 3 no optimal Alive 175 no 175 A
T302 47 III C 2 yes optimal Dead 17 yes 17 B
T303 57 IV C 3 yes incomplete Dead 9 yes 8 B
T304 51 III C 3 yes incomplete Dead 14 yes 14 A
T305 74 IIIb C 3 yes optimal Dead 60 yes 47 B
T306 48 IIIa C 3 yes optimal Alive 104 no 104 B
T308 45 IV E 2 yes optimal Dead 19 yes 9 B
T309 47 IIIc E 2 yes optimal Dead 41 yes 21 B
T310 74 IIIb E 2 yes optimal Dead 57 yes 57 B
T311 67 IIIc E 3 yes minimal Dead 61 yes 22 B
T312 53 IIIb E 3 yes optimal Dead 28 yes 28 B
T313 67 III M 1 yes optimal Dead 22 yes 22 A
T314 76 IV M 2 yes optimal Dead 15 yes 13 A
T315 70 IIIc S 1 yes optimal Alive 136 no 136 A
T316 76 IV S 1 yes optimal Alive 22 yes 22 A
T317 80 IIIc S 2 yes incomplete Dead 6 yes 5 B
T318 61 IIIc S 3 yes unknown Dead 5 yes 12 B
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oligonucleotides (GPL8693, Agilent Technologies, Palo Alto,
CA, USA), and hybridization was performed using the oligo
array CGH/Chip-Chip Hybridization Kit 25 (Agilent). Each
slide contained 2 arrays and one reference sample was hybrid-
ized per three tumor samples, as previously described [13].
Samples were hybridized overnight, were washed and
subsequently scanned using a microarray scanner (Agi-
lent, G2505B). Raw data of all the arrays performed are
publicly available in the GEO database (accession num-
ber GSE24418).
2.3 Data analysis
Array CGH quality was assessed by means of the median
absolute deviation (MAD) of the log2 ratios of a chromo-
some arm without a breakpoint [14]. Whereas all MAD
values of the copy number changes on the q-arm of chro-
mosome two were between 0.17 and 0.43, the MAD value
of one advanced stage sample was 0.70. This sample and its
early stage match were therefore excluded from further
analyses, leaving 16 early versus 16 advanced stage cases.
Fig. 1 The frequencies of copy
number gains in 16 early and 16
advanced stage ovarian cancer
samples are plotted at the top of
Panel A. The frequencies were
tested for a difference between
both stages and the false
discovery rate corrected p-value
is displayed. At the bottom of
Panel A the analogue is shown
for copy number losses. Panel B
shows the array CGH profiles
of all samples grouped per stage
with blue indicating a loss,
black a normal and yellow a
gain in DNA copy number
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With this set of 32 samples power analysis has been per-
formed. Log2ratios were median normalized across array
[13], wave patterns were smoothed [15]. Segmentation was
performed by using circular binary segmentation (CBS),
since this method has shown to substantially reduce the
false positives caused by the local trends in the data [16,
17]. Mode normalization was performed on the segmented
data prior to automated identification of losses, gains and
amplifications [16]. Dimension reduction was achieved by
summarizing into regions with a threshold of 0.01, in order
to accept a maximum of 1 % information loss. The frequen-
cies of aberrations in both groups were estimated, and the
false discovery rate corrected p-values (Chi-square) of a
difference in occurrence of aberrations between both groups
were calculated after dividing the genome into regions [18,
19]. Using a FDR of 15 %, more than 50 % of discrimina-
tive aberrations will be detected [20]. To test whether ad-
vanced stage progresses from early stage, we tested whether
the odds for aberrations in advanced stage samples were
genome-wide higher than for the early stage samples (see
supplementary materials for details). Weighted unsupervised
clustering of called array CGH data was performed as
described previously [21, 22]. Clusters found were correlat-
ed to overall and progression free survival using Kaplan-
Meier survival analysis with log rank testing (SPSS software
package version 17.0, Chicago, IL, USA). All other analy-
ses were performed in the statistical framework R [23].
3 Results
The patterns of aberrations in the advanced stage group
mirrored those in the early stage group. Moreover, virtually
all of the genomic aberrations were more frequent in the
advanced stage group (Fig. 1a); the odds for aberrations
were genome-wide significantly (p00.012 higher in ad-
vanced stage ovarian cancer than in early stage disease
(See supplementary materials for details). When compared
on patient level (Fig. 1b) the tumor profiles are heteroge-
neous. However, when stratified per FIGO stage according
to histological subtype (Fig. 2) the profiles display more
similarity. Furthermore, Fig. 2 shows that progression of
aberrations is most pronounced in the clearcell and endome-
trioid subtypes.
Fig. 2 Array CGH profiles ordered per histological type and FIGO stage. Blue indicates a loss, black a normal and yellow a gain in DNA copy
number
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When analysing the clinical and pathological charac-
teristics of the tumors, we found the survival rate in
patients with advanced stage ovarian cancer to be sig-
nificantly lower than in patients with early stage cancer
(p<0.001), as expected. Contrastingly, stratification of
the samples according to histological subtype yielded
no significant difference in survival. However, patients
with well-differentiated (grade one) tumors had signifi-
cantly better survival than patients with intermediate and
poorly (grades two and three) differentiated tumors
combined (p00.044).
In order to study if and how aberrations correlate to
the clinical behaviour of the tumors, weighted clustering
of called array CGH data was performed and yielded
two distinct groups of 19 tumor samples in cluster A
and 13 in cluster B (Fig. 3). Cluster A contained 5
advanced and 14 early stage tumors, of which four
and two, respectively had a recurrence. Cluster B
contained 11 advanced and two early stage tumors of
which ten and one, respectively had a recurrence (Pear-
son Chi-square for distribution of FIGO stage between
the clusters p00.001). With a mean survival of
142.0 months (95 %CI 112.7–171.2), patients in cluster
A had a significantly (Mantel Cox log rank p00.002)
better survival than patients in cluster B (43.0 months,
95 %CI 27.4–58.6) (Fig. 4).
4 Discussion
Early and advanced stage ovarian carcinomas were com-
pared with respect to chromosomal copy number aberrations
measured by array CGH. Due to their distinct clinical
Fig. 3 Heatmap of unsupervised clustering. Blue indicates a loss,
black a normal, and yellow a gain in DNA copy number. The dendro-
gram on the right shows the similarity between the array CGH profiles.
Left of the heatmap the tumor characteristics (FIGO stage, histological
type and tumor differentiation grade) are displayed. A partition of the
32 ovarian cancer patients in cluster A and cluster B is found. In cluster
A samples T104, T110, T304, T313, T314 and T316 had progression.
In cluster B samples T117, T302, T303, T305, T308, T309, T310,
T311, T312, T317 and T318 had progression
Fig. 4 Kaplan-Meier plot based on cluster A (n019) and cluster B (n0
13) identified by unsupervised clustering of array CGH data. The p-
value was calculated using the Mantel-Cox log rank test
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presentation, we hypothesised that early and advanced stage
ovarian cancer develop through separate molecular path-
ways. Aberrations were more frequent in advanced stage
and there were virtually no aberrations in early stage that
were not found in advanced stage. This finding suggests that
advanced stage disease either progresses from early stage
disease or from a common precursor lesion. This validates
earlier findings in an independent data set using low reso-
lution array CGH [6].
Unsupervised clustering of genomic aberrations signifi-
cantly discriminated early from advanced stage samples.
However, to differentiate molecular subtypes based on array
CGH data, independent and high-resolution validation stud-
ies are necessary.
Depending on the scoring criteria, microsatellite instabil-
ity (MSI) has been reported in 0–24 % of ovarian cancers
[24–26], and little is known about their biological and
clinical significance. However we did not test for MSI, so
we can not exclude that in our samples there is MSI that
could have influenced the outcome.
Ovarian carcinomas have been divided into subtypes by
Shih and Kurman. [27] They propose a stratification based
on clinical and histological characteristics in type I and type
II tumors. Type I tumors are less frequent and are believed to
be slow growing, generally confined to the ovary at diag-
nosis and genetically relatively stable. Histologically, type I
tumors would consist of low-grade micropapillary serous
carcinoma, mucinous, endometrioid, and clear cell carcino-
mas and would be associated with mutations in KRAS,
BRAF, PTEN, and beta-catenin. Type II tumors would form
the most common type of ovarian carcinomas and are rap-
idly growing, highly aggressive and genetically unstable.
They would be high-grade serous carcinoma, malignant
mixed mesodermal tumors and undifferentiated carcinomas
and are associated with TP53 mutations. As our study is
based on FIGO stage 1 tumours we cannot compare cluster
A and B with type I and II. However, we show that our
study population (mainly consisting of type I tumours) can
be further subdivided by array CGH into patients with good
and poor overall survival.
The survival times differed significantly between both
clusters. This finding suggests that the comparative genomic
hybridization data of an ovarian carcinoma has the potency
of being of clinical value in the future.
In conclusion, in this study we showed advanced stage
ovarian cancer either progresses from early stage disease or
from a common precursor lesion. We reject the hypothesis
that the two stages might develop through distinct carcino-
genic molecular events. Furthermore, when we divided
patients in two groups solely on their genomic aberrations,
we found these groups to differ significantly in survival.
Since copy number analysis can be performed on easy to
gain pre-treatment FFPE ovarian cancer tissue, array CGH
data has the potency to identify patients with a worse
prognosis.
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